Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis
While immune checkpoint inhibitors (ICI) can lead to sustained responses in metastatic renal cell carcinoma (mRCC), the optimal duration of therapy remains unknown. We aimed to examine treatment-free survival (TFS) in objective responders who discontinued ICI and to explore factors that may impact o...
Saved in:
| Main Authors: | Alice Tzeng, Tony H Tzeng, Moshe C Ornstein |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/9/10/e003473.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Paradoxical Effect of Myosteatosis on the Immune Checkpoint Inhibitor Response in Metastatic Renal Cell Carcinoma
by: Jiwoong Yu, et al.
Published: (2025-04-01) -
Resistance to immune checkpoint inhibitors in the treatment of metastatic renal cancer
by: A. A. Izmailov, et al.
Published: (2023-09-01) -
Sarcoid‐Like Reaction (SLR) Associated With Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma
by: Kanta Fukushima, et al.
Published: (2025-05-01) -
Graph-Based Immune Checkpoint Inhibitor Response Prediction Model for Metastatic Renal Cell Carcinoma Patients
by: Sandra Alonso, et al.
Published: (2025-01-01) -
Impact of Antibiotics on the Efficacy of Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
by: Do Gyeong Lim, et al.
Published: (2023-12-01)